CA3210294A1 - Compound and radioactive labeling compound - Google Patents
Compound and radioactive labeling compound Download PDFInfo
- Publication number
- CA3210294A1 CA3210294A1 CA3210294A CA3210294A CA3210294A1 CA 3210294 A1 CA3210294 A1 CA 3210294A1 CA 3210294 A CA3210294 A CA 3210294A CA 3210294 A CA3210294 A CA 3210294A CA 3210294 A1 CA3210294 A1 CA 3210294A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- psma
- formula
- atomic group
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021034026 | 2021-03-04 | ||
| JP2021-034026 | 2021-03-04 | ||
| JP2021-146833 | 2021-09-09 | ||
| JP2021146833 | 2021-09-09 | ||
| PCT/JP2022/009003 WO2022186311A1 (ja) | 2021-03-04 | 2022-03-02 | 化合物及び放射性標識化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3210294A1 true CA3210294A1 (en) | 2022-09-09 |
Family
ID=83155351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3210294A Pending CA3210294A1 (en) | 2021-03-04 | 2022-03-02 | Compound and radioactive labeling compound |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240174622A1 (https=) |
| EP (1) | EP4303213A4 (https=) |
| JP (1) | JPWO2022186311A1 (https=) |
| KR (1) | KR20230154183A (https=) |
| AU (1) | AU2022228911A1 (https=) |
| CA (1) | CA3210294A1 (https=) |
| TW (1) | TW202302542A (https=) |
| WO (1) | WO2022186311A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196175A4 (en) * | 2020-08-14 | 2025-07-30 | Clarity Pharmaceuticals Ltd | RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION |
| CN116285684B (zh) * | 2023-05-15 | 2023-08-08 | 四川绚度眼视光科技有限公司 | 一种多功能超亲水涂层及其制备方法与应用 |
| CN116870176B (zh) * | 2023-08-03 | 2025-08-12 | 浙江大学 | PSMA靶向的PSMA-PARPi偶联物及制备方法和应用 |
| WO2025220711A1 (ja) * | 2024-04-17 | 2025-10-23 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物 |
| WO2026014283A1 (ja) * | 2024-07-09 | 2026-01-15 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CA2760839C (en) | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| CN108699108B (zh) | 2016-03-01 | 2022-04-08 | 国立大学法人千叶大学 | 放射性标记药物 |
| MX2019005742A (es) * | 2016-11-23 | 2019-09-13 | Cancer Targeted Tech Llc | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
| EP3609541A4 (en) * | 2017-04-05 | 2021-04-07 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| CA3060143A1 (en) * | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| US11167050B2 (en) | 2017-09-26 | 2021-11-09 | National University Corporation Chiba University | Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound |
| US20200339625A1 (en) * | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| HRP20230604T1 (hr) * | 2018-03-30 | 2023-09-29 | Futurechem Co., Ltd. | Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| JP7699542B2 (ja) * | 2018-11-20 | 2025-06-27 | コーネル ユニバーシティー | 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用 |
| US12427209B2 (en) * | 2018-12-18 | 2025-09-30 | Provincial Health Services Authority | Dual mode 18F-labelled theranostic compounds and uses thereof |
| MX2021008230A (es) | 2019-01-07 | 2021-08-11 | Astellas Pharma Inc | Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5. |
| CN114364405B (zh) * | 2019-04-26 | 2024-07-16 | 五一一制药股份有限公司 | 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂 |
| AU2021230210A1 (en) * | 2020-03-04 | 2022-09-22 | Kyoto University | Compound and radioactive labeling compound |
-
2022
- 2022-03-02 AU AU2022228911A patent/AU2022228911A1/en active Pending
- 2022-03-02 KR KR1020237029291A patent/KR20230154183A/ko active Pending
- 2022-03-02 US US18/548,716 patent/US20240174622A1/en active Pending
- 2022-03-02 CA CA3210294A patent/CA3210294A1/en active Pending
- 2022-03-02 JP JP2023503935A patent/JPWO2022186311A1/ja active Pending
- 2022-03-02 EP EP22763364.1A patent/EP4303213A4/en active Pending
- 2022-03-02 WO PCT/JP2022/009003 patent/WO2022186311A1/ja not_active Ceased
- 2022-03-03 TW TW111107807A patent/TW202302542A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202302542A (zh) | 2023-01-16 |
| WO2022186311A1 (ja) | 2022-09-09 |
| JPWO2022186311A1 (https=) | 2022-09-09 |
| KR20230154183A (ko) | 2023-11-07 |
| AU2022228911A1 (en) | 2023-09-21 |
| EP4303213A4 (en) | 2024-09-18 |
| EP4303213A1 (en) | 2024-01-10 |
| US20240174622A1 (en) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3210294A1 (en) | Compound and radioactive labeling compound | |
| AU2023203682B2 (en) | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | |
| JP7340459B2 (ja) | 新規ｐｓｍａ結合剤及びその使用 | |
| JP7729609B2 (ja) | 診断および放射性核種治療剤としての前立腺特異的膜抗原（ｐｓｍａ）阻害剤 | |
| TWI908773B (zh) | 化合物及放射性標誌化合物 | |
| CN108699108B (zh) | 放射性标记药物 | |
| CA3071315A1 (en) | Dual mode radiotracer and -therapeutics | |
| WO2011031073A2 (ko) | 신규한 테트라아자 거대고리 화합물, 제조방법 및 그 용도 | |
| CA3207132A1 (en) | Dual mode radiotracer and -therapeutics | |
| WO2024063648A1 (en) | Platform and scaffold for FAP targeting agents | |
| EP2970154B1 (en) | Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications | |
| JP2015086213A (ja) | 放射性核種標識オクトレオチド誘導体 | |
| CA3214915A1 (en) | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | |
| WO2013060793A1 (en) | Bifunctional ligands for radiometals | |
| WO2022233768A1 (en) | Precursor and radiotracer for neuroendocrine theranostics | |
| WO2011102626A2 (ko) | 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 | |
| RU2823164C2 (ru) | Соединение пептидной природы, обладающее способностью связываться с псма, способ его получения и применения | |
| HK40078050A (en) | Compound and radioactive labeling compound | |
| HK40092961A (zh) | 化合物及放射性标记化合物 | |
| CN116940557A (zh) | 化合物及放射性标记化合物 | |
| Riss et al. | A concise synthesis procedure to furnish multi-gram amounts of hexadentate, bivalent DO2A-based chelators | |
| Lodhi | Synthesis and In Vivo Biological Evaluation of 99mTc (I) Tri-carbonyl Based Radiopharmaceuticals for SPECT Imaging | |
| WO2025220711A1 (ja) | 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物 | |
| KR20250049308A (ko) | 방사성 의약품용 규소계 불화물 수용기 | |
| AU2023344993A1 (en) | Platform and scaffold for FAP targeting agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250214 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250214 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250214 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260202 |